Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.55 |
| ▸ | DRD4 | P21917 | 10/20 | 0.55 |
| ▸ | DRD3 | P35462 | 10/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464670 | 0.89 | POLB (0.51) | DRD2DRD4DRD3POLBADRB2 | |
| SCHEMBL13960709 | 0.88 | DRD2 (0.50) | DRD2DRD4DRD3POLBADRB2 | |
| SCHEMBL4489307 | 0.85 | DRD2 (0.49) | DRD2DRD4DRD3POLB | |
| SCHEMBL13960710 | 0.82 | POLB (0.58) | DRD2DRD4DRD3POLBCHRM2 | |
| SCHEMBL30806382 | 0.80 | POLB (0.66) | DRD2DRD4DRD3POLB | |
| SCHEMBL4480619 | 0.79 | POLB (0.49) | DRD2DRD4DRD3POLBADRB2 | |
| SCHEMBL4697249 | 0.79 | ADRB1 (0.49) | DRD2DRD4DRD3ADRB1CHRM1 | |
| SCHEMBL30100689 | 0.79 | POLB (0.71) | DRD2DRD4DRD3POLBSMPD1 | |
| SCHEMBL30100692 | 0.79 | POLB (0.71) | DRD2DRD4DRD3POLBSMPD1 | |
| SCHEMBL4328336 | 0.79 | POLB (0.71) | DRD2DRD4DRD3POLBSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603880-B1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1603880-A1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-14 | — | — | EP | claimed |
| US-6943169-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | claimed |
| WO-2004080969-A1 | QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | claimed |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | ROCHE PALO ALTO LLC | 2004-09-23 | — | — | US | claimed |
| US-7476675-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476675-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476675-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1603880-B1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1603880-A1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-11-24 | — | — | US | disclosed |
| US-6943169-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2004080969-A1 | QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | ROCHE PALO ALTO LLC | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | NQO2, UGT1A8, UGT1A1 | DRD2 1307/4885DRD4 893/4885DRD3 1231/4885 |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | RECQL, NQO2, QRFPR | DRD2 720/4885DRD4 555/4885DRD3 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.